While complying with local directives, Cellecta is fully operational. Normal turnaround times have not been affected by COVID-19 more >
MilliporeSigma Announces Licensing of CRISPR Technology to CELLECTA, Inc.
October 5, 2021
MilliporeSigma's Life Science Business Sector announced the signing of a licensing agreement for its CRISPR-mediated knock-in technology with Cellecta, Inc.
November 5, 2020 (PR Newswire)
Cellecta today announced the launch of its new RNA Spatial Profiling Service using NanoString’s GeoMx® Cancer Transcriptome Atlas (CTA) on the GeoMx Digital Spatial Profiler.
CELLECTA, Inc. Launches the First Commercially Available Dual-sgRNA Libraries for CRISPRa and CRISPRi Genetic Screens
June 26, 2019 (PR Newswire)
Cellecta today announced the launch of the first commercially available dual sg-RNA libraries designed for CRISPR activation and CRISPR interference genetic screens. These new pooled libraries enhance activation or repression of genes producing more robust results from genetic screens.